The Economic Burden Of Rare Diseases: Quantifying The Sizeable Collective Burden And Offering Solutions February 01, 2022 Share this page Each study employed its own methodology and approach to capture the cost burden of rare diseases in the US, and all four aligned in their core conclusions Value Assessment Related Articles What’s Next in 2025? Rare Disease Policy Opportunities in Congress July 29, 2025 New Study Measures Economic Impact of Delayed Diagnosis of Rare Diseases September 14, 2023 EveryLife Issues Statement on House Energy & Commerce Hearing March 17, 2022 See All News